当前位置: 首页 > 详情页

Angiotensin II-Induced Egr-1 Expression is Suppressed by Peroxisome Proliferator-Activated Receptor-gamma Ligand 15d-PGJ(2) in Macrophages

文献详情

资源类型:

收录情况: ◇ SCIE

机构: [1]Capital Med Univ, Dept Pathol & Pathophysiol, Key Lab Remodeling Related Cardiovasc Dis, Sch Basic Med Sci,Beijing AnZhen Hosp, Beijing, Peoples R China; [2]Dalian Med Univ, Affiliated Hosp 1, Inst Cardiovasc Dis, Dept Cardiol, Dalian 116011, Peoples R China; [3]Dalian Med Univ, Sch Publ Hlth, Ctr Prevent & Control Noncommunicable Chron Dis, Dept Food Hyg & Nutr, Dalian 116011, Peoples R China
出处:
ISSN:

关键词: Egr-1 Angiotensin II Inflammation Macrophages PPAR-gamma ligand 15d-PGJ(2)

摘要:
Background/Aims: Angiotensin II (Ang II) plays a critical role in regulating vascular inflammatory diseases, such as atherosclerosis and hypertension. Early growth response-1 (Egr-1) is an immediate early gene that acts as a master switch for the inflammatory response. However, the role of Ang II in regulating Egr-1 expression in macrophages, and the effect of peroxisome proliferators-activated receptor-gamma (PPAR-gamma) ligand 15d-PGJ(2) in this process remain to be investigated. Methods and Results: We showed that Ang II significantly up-regulated the expression of Egr-1 in RAW264.7 macrophages, and this effect was markedly attenuated by Eprosartan (an AT1R blocker), SP600125 (a JNK-specific inhibitor) and PD98059 (an ERK-specific inhibitor). Moreover, treatment of macrophages with 15d-PGJ2, a natural PPAR-gamma ligand, significantly reduced Ang II-induced expression of Egr-1 and its inflammatory gene targets (IL-1 beta, TNF-alpha, TGF-beta, MCP-1 and ICAM-1) through PPAR-gamma activation and ROS formation. In addition, 15d-PGJ(2) treatment markedly inhibited Ang II-induced macrophage migration and proliferation. Conclusions: This study for the first time demonstrates that Ang II can induce the expression of Egr-1 via AT1R/JNK and ERK signaling pathways. Activation of PPAR-gamma by 15d-PGJ(2) suppresses Egr-1-mediated proinflammatory response, and may be a novel therapeutic strategy for treatment of vascular inflammatory diseases. Copyright (C) 2015 S. Karger AG, Basel

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2014]版:
大类 | 3 区 生物
小类 | 3 区 生理学 4 区 细胞生物学
最新[2023]版:
JCR分区:
出版当年[2013]版:
Q1 PHYSIOLOGY Q2 CELL BIOLOGY
最新[2023]版:
Q2 PHYSIOLOGY Q3 CELL BIOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2013版] 出版当年五年平均 出版前一年[2012版] 出版后一年[2014版]

第一作者:
第一作者机构: [1]Capital Med Univ, Dept Pathol & Pathophysiol, Key Lab Remodeling Related Cardiovasc Dis, Sch Basic Med Sci,Beijing AnZhen Hosp, Beijing, Peoples R China;
通讯作者:
通讯机构: [2]Dalian Med Univ, Affiliated Hosp 1, Inst Cardiovasc Dis, Dept Cardiol, Dalian 116011, Peoples R China; [3]Dalian Med Univ, Sch Publ Hlth, Ctr Prevent & Control Noncommunicable Chron Dis, Dept Food Hyg & Nutr, Dalian 116011, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:16409 今日访问量:0 总访问量:869 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院